TMP/SMX

DRUG2 trials

Sponsors

University of Washington, Locus Biosciences

Conditions

Urinary Tract InfectionUrinary Tract Infections

Phase 2

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

RecruitingNCT05488340

Locus BiosciencesUrinary Tract Infections

Start: 2022-07-13End: 2027-12-01Target: 318Updated: 2026-09-14

Unknown Phase

Single Dose Monurol for Treatment of Acute Cystitis

CompletedNCT00976963

University of WashingtonUrinary Tract Infection

Start: 2009-09-17End: 2016-12-27Updated: 2023-06-05

Related Papers

Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.

2024-08-0939 citations